Krithika Subramanian, PhD

An in-depth analysis of the genetics of DMD and disease modifiers such as the NF-kB pathway in patients with Duchenne muscular dystrophy.

Although there are no cures for MS at present, the treatment landscape has changed significantly, with over a dozen approved disease-modifying therapies (DMTs) representing multiple classes of agents with different mechanisms of action.

Krithika Subramanian, PhD discusses the orexin receptor pathway, signals within orexin receptors, and much more surrounding the clinical application of orexin receptor antagonists.

After a long period of time with minimally effective treatments for migraine, the growing understanding of the CGRP pathway has opened the door to a variety of new and highly efficacious therapies for patients with chronic and episodic forms of disease.

VMAT2, given its role in presynaptic packaging, storage, and release of dopamine, has emerged as a promising target for therapeutic interventions to manage movement disorders.